MTOR and cancer: Metformin-mediated anti-cancer activities have been associated with both systemic and cellular regulatory activities, including lowering insulin levels, increasing insulin sensitivity, and activation of AMP-activated protein kinase (AMPK)/inhibition of mammalian target of rapamycin (mTOR) [3, 7].